A1 Refereed original research article in a scientific journal

Supersensitive photon upconversion based immunoassay for detection of cardiac troponin I in human plasma




AuthorsRaiko Kirsti, Lyytikäinen Annika, Ekman Miikka, Nokelainen Aleksi, Lahtinen Satu, Soukka Tero

PublisherELSEVIER

Publication year2021

JournalClinica Chimica Acta

Journal name in sourceCLINICA CHIMICA ACTA

Journal acronymCLIN CHIM ACTA

Volume523

First page 380

Last page385

Number of pages6

ISSN0009-8981

DOIhttps://doi.org/10.1016/j.cca.2021.10.023

Web address https://doi.org/10.1016/j.cca.2021.10.023

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/67873883


Abstract

Background and aims: Upconverting nanoparticles (UCNPs) are attractive reporters for immunoassays due to their excellent detectability. Assays sensitive enough to measure baseline level of cardiac troponin I cTnI in healthy population could be used to identify patients at risk for cardiovascular disease. Aiming for a cTnI assay of such sensitivity, the surface chemistry of the nanoparticles as well as the assay reagents and the protocol were optimized for monodispersity of the UCNP antibody conjugates (Mab UCNPs) and to minimize their non-specific interactions with the solid support.

Materials and methods: UCNPs were coated with poly(acrylic acid) via two-step ligand exchange and conjugated with monoclonal antibodies. The conjugates were applied in a microplate-based sandwich immunoassay using a combination of two capture antibodies to detect cTnI. Assay was evaluated according to guidelines of Clinical & Laboratory Standards Institute.

Results: The limit of detection and limit of blank of the assay were 0.13 ng/L and 0.01 ng/L cTnI, respectively. The recoveries were >90% in spiked plasma in the linear range. The within- and between-run imprecisions were <10%.

Conclusion: The results demonstrate that UCNPs enable quantification of cTnI concentrations expected in plasma of healthy individuals and could be used to identify patients at risk for cardiovascular disease.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 21:18